ArticlePostepy w kardiologii interwencyjnej = Advances in interventional cardiology2025
Application of pre-prescription review of suspicious data via intelligent supervision platform for secondary prevention of cardiovascular diseases based on evidence-based medicine.
Article in Postepy w kardiologii interwencyjnej = Advances in interventional cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Secondary prevention of cardiovascular disease (CVD) requires strict adherence to evidence based medication regimens to reduce recurrent events. Prescription errors or irrational drug use can compromise outcomes, highlighting the need for effective pre-prescription review strategies. Aim: This study aimed to assess the application of pre-prescription review of suspicious data via an intelligent supervision platform based on evidence-based medicine (EBM) for secondary prevention of CVD. Material and methods: One hundred and forty CVD patients requiring secondary prevention were randomized to a control group (traditional prescription review) and an observation group (EBM-based intelligent platform pre-review). We compared between-group differences in medication appropriateness, rational drug use rates, prescription modification rates, adverse cardiovascular events, and patient satisfaction before and after review. Results: Post-review assessments revealed significant improvements in both groups across all measured outcomes, including medication appropriateness, rational drug use rates, and patient satisfaction, alongside reductions in Medication Appropriateness Index inappropriateness rates, prescription modifications, and cardiovascular adverse events. However, the observation group demonstrated markedly superior outcomes compared to traditional review: higher medication appropriateness and rationality scores, greater adherence to rational drug use standards, and significantly lower rates of prescription modifications and adverse events. Patient satisfaction scores were also higher in the observation group, confirming the platform's clinical and operational advantages. Conclusions: EBM based intelligent supervision platform pre review markedly enhances medication appropriateness and rational drug use in CVD secondary prevention, reduces prescription modifications and adverse cardiovascular events, and improves patient satisfaction, offering clear clinical and operational benefits over traditional review methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.